Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Peremyshl – page 3

37 clinical trials in Peremyshl, Poland. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Peremyshl at a glance
37
clinical trials
  • Not yet recruiting0
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

37 trials in Peremyshl

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan, Durvalumab, and Carboplatin for Advanced Non-Small Cell Lung Cancer in Patients Without Actionable Genomic Alterations

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

HER2 mutant non-small cell lung cancer

Not recruiting

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing MK-7684A with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Clear cell renal cell carcinoma

Not recruiting

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Adenocarcinoma gastric

Not recruiting

Study on the Effectiveness and Safety of Lenvatinib, Pembrolizumab, and Chemotherapy for Patients with Advanced or Metastatic Gastroesophageal Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Merck Sharp & Dohme LLC

Prostate cancer

Not recruiting

Study of Pembrolizumab and Enzalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study Comparing DZD9008 and Chemotherapy for First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Mutation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Dizal Pharmaceutical Co. Ltd.

Hepatocellular carcinoma

Not recruiting

Study on the Safety and Effectiveness of MK-1308A, Pembrolizumab, and Lenvatinib for Patients with Advanced Liver Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Acute coronary syndrome

Not recruiting

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Small cell lung cancer

Not recruiting

Study of MK-7684A, Etoposide, and Platinum Drugs for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Peremyshl

What the registry says about research in the country

01 Oncology - Lung Cancer

Multiple clinical trials focusing on non-small cell lung cancer (NSCLC) evaluating novel immunotherapy combinations and treatments. Research includes studies of advanced metastatic cases and post-surgical therapeutic approaches.

  • Metastatic NSCLC treatments
  • Post-surgical therapy optimization
  • Immunotherapy combinations

Investigating breakthrough treatments for both early-stage and advanced lung cancer patients.

02 Urological Oncology

Innovative research in bladder cancer treatment, particularly focusing on non-muscle invasive cases. Studies evaluate new intravesical therapies and treatment approaches for patients unresponsive to standard care.

  • High-risk bladder cancer management
  • Novel therapeutic combinations
  • Treatment-resistant cases

Advanced therapeutic options for various stages of bladder cancer.

03 Cardiovascular Research

Studies addressing atrial fibrillation and cardiovascular conditions, focusing on new anticoagulation approaches and post-heart attack treatments. Research aims to improve patient outcomes and reduce complications.

  • Stroke prevention
  • Anticoagulation therapy
  • Post-cardiac event care

Evaluating next-generation treatments for common cardiovascular conditions.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.